Tag: WuXi Biologics
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
APS Industrial expands regional footprint with Control Technologies acquisition
APS Industrial (APS) is expanding its regional presence through the acquisition of Albury-based Control Technologies, a move the industrial products supplier said will strengthen its local service capability and support further investment in warehousing, stockholding and technical support.
